Drug Development
Despite Sanofi CEO Paul Hudson’s confidence in vaccines, the French pharma has cut at least one mRNA flu shot program.
FEATURED STORIES
Together with robust data-driven modeling, rethinking regulation and data use could push forward a notoriously challenging field.
From opening new therapeutic mechanisms to repairing neuronal damage, investigational molecules from Ventyx Therapeutics, AC Immune, Gain Therapeutics and more could shape the future of Parkinson’s disease treatment.
As drug candidates discovered via AI move into later-stage clinical trials, the technology seems to be doing as promised: speeding drug development.
Subscribe to ClinicaSpace
Clinical trial results, research news, the latest in cancer and cell and gene therapy, in your inbox every Monday
THE LATEST
The Mu variation is the fifth strain to be designated as a “variant of interest” by the World Health Organization.
Shares of Forte Biosciences plunged more than 80% in premarket trading after the company announced failure to demonstrate statistical significance of Phase II atopic dermatitis trial.
Heading into the Labor Day weekend in the U.S., there’s still plenty of COVID-19 news. Here’s a look.
The approval was built on data from the Phase III ASPEN trial that compared Brukinsa to ibrutinib in a total of 201 patients. Here’s more about the drug.
The company sent the medication to a Florida neurology clinic free of charge.
Pfizer dosed its first patients in a Phase III trial assessing a single dose of its investigational RSV bivalent prefusion F subunit vaccine candidate (RSVpreF) in adults ages 60 and above.
Shares of Assembly Biosciences have fallen more than 20% in premarket trading after the company discontinued the development of a hepatitis B therapeutic candidate.
A study published in The Lancet Infectious Diseases found that the Pfizer-BioNTech, Oxford-AstraZeneca or Moderna vaccines resulted in a drop in “long-haul” COVID-19 by 50%.
Takeda said that Phase III PANTHER, which studied the effectiveness of pevonedistat for different types of leukemia, did not produce significant results in terms of event-free survival.
FDA greenlit Janssen’s Invega Hafyera, the first long-acting antipsychotic drug of its kind that provides six months’ control of symptoms with a single dose.